CADL
Candel Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$12.78
−1.46%Aug 13, 2026, 12:05 UTC
Candel Therapeutics announced its financial results for the second quarter ended June 30, 2026.
Source:Jun 30, 2026, 12:05 UTC
Candel Therapeutics initiated a global pivotal Phase 3 AURORA trial evaluating aglatimagene besadenovec (CAN-2409) in advanced non-small cell lung cancer patients with inadequate response to immune checkpoint inhibitors.
Source:Jun 1, 2026, 20:05 UTC
Candel Therapeutics granted stock options to three new employees on May 31, 2026.